By Fineline Cube 
China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval filing for its generic version of AbbVie’s Allergan’s Vuity (pilocarpine) to the National Medical Products Administration (NMPA). This marks a significant step in bringing the presbyopia treatment to the Chinese market.
Mechanism of Action
Vuity is an M-cholinergic receptor agonist that works by activating muscarinic receptors in the iris sphincter and ciliary muscles. This action induces pupil constriction to enhance depth of focus for near-intermediate vision while maintaining light responsiveness and improving accommodative ability. It is specifically indicated for the treatment of presbyopia in adults.
Market Background
Pilocarpine gained recognition as the world’s first presbyopia treatment when it received FDA approval in 2021. Currently, it is not commercially available in China. Taienkang Pharma has taken a leading position as the first domestic company to have a generic application accepted for review by the NMPA.-Fineline Info & Tech